Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving regulatory approvals and fulfilling customary ...

The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...

German pharmaceutical giant Merck has completed a €3 billion ($3. 5 billion) takeover of US biopharmaceutical company ...

Merck KGaA, Darmstadt, Germany has closed the acquisition of SpringWorks Therapeutics Inc. for an enterprise value of $3.4 billion.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 ...

In other recent news, SpringWorks Therapeutics, Inc. has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of ...

Explore SpringWorks Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for SWTX. WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last ...

The Fiera Capital SMID Cap Growth SMA returned -10.7% (net of fees), and slightly outperformed its benchmark for Q1 2025.

Patients with rare diseases are increasingly working to find and fund their own cures. But should they have to?